Similar articles

Abstract: Aim: To observe effects of angiotensin (Ang) II receptor antagonist (AT1) irbesartan and angiotensin-converting enzyme (ACE) inhibitor perindopril on rat myocardium calcineurin expression and sarcoplasmic reticulum Ca²⁺-ATPase activity in the model of pressure-overload cardiac hypertrophy. Methods: Forty male adult Sprague Dawley rats were divided into 5 groups. One group was treated by sham operation; four groups were myocardium hypertrophy cases caused by banding aortic above renal artery. Drugs were given one week after operation. Group 1: sham group, rats (n=8) were gavaged with normal saline 2 ml/(kg·d) (ig); Group 2: control group, rats (n=8) were treated with normal saline 2 ml/(kg·d) (ig); Group 3: rats (n=8) were given perindopril 2 mg/(kg·d) (ig); Group 4: rats (n=8) were treated with irbesartan 20 mg/(kg·d) (ig); Group 5: rats (n=8) were given irbesartan 20 mg/(kg·d) plus perindopril 2 mg/(kg·d) (ig). Morphometric determination, calcineurin expression and sarcoplasmic reticulum Ca²⁺-ATPase activity were done at the end of 6 week of drug intervention. Expression of calcineurin in myocardium was detected by immunohistochemistry. Results: Left ventricular mass index (LVMI), transverse diameter of myocardial cell (TDM), calcineurin activity were remarkably decreased after drug intervention and this decrease was most remarkable in the combination drug therapy group. sarcoplasmic reticulum Ca²⁺-ATPase activity was increased after drug intervention, especially in the combined drug therapy group. calcineurin expression in myocardium was remarkably decreased after drug intervention. LVMI was positively correlated with TDM and calcineurin, negatively correlated with sarcoplasmic reticulum Ca²⁺-ATPase. Conclusion: These data suggest that irbesartan and perindopril inhibit cardiac hypertrophy through the increased activity of sarcoplasmic reticulum Ca²⁺-ATPase and decreased expression of calcineurin. Their combination had better effects on regressing of ventricular hypertrophy.

[1] Barnes, D.M., Dublin, E.A., Fisher, C.J., Levison, D.A., Millis, R.R., 1993. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum. Pathol., 24(5):469-476.

[2] Bastie, D., Levitsky, D., Rappaport, L., 1990. Function of the sarcoplasmic reticulum and expression of its Ca²⁺-ATPase gene in pressure overload-induced cardiac hypertrophy in the rat. Circ. Res., 66(2):554-564.

[3] de Windt, L.J., Lim, H.W., Bueno, O.F., Liang, Q., Delling, U., Braz, J.C., Glascock, B.J., Kimball, T.F., Monte, F.D., Hajjar, R.J., Molkentin, J.D., 2001. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. USA, 98:3322-3327.

[4] Devereux, R.B., 1995. Left ventricular geometry, pathophysiology and prognosis. J. Am. Coll. Cardiol., 25(4):885-887.

[5] Doering, C.W., Jalil, J.E., Janicki, J.S., 1988. Collagen network remodelling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy. Cardiovasc. Res., 22(10):686-695.

[6] Grossman, W., Jones, D., McLaurin, L.P., 1975. Wall stress and patterns of hypertrophy in the human left ventricle. J. Clin. Invest., 55:56-64.

[7] James, P., Inui, M., Tada, M., Chiesi, M., Carafoli, E., 1989. Nature and site of phospholamban regulation of the Ca²⁺ pump of sarcoplasmic reticulum. Nature, 342(6245):90-92.

[8] Jones, L.R., Besch, H.R., Fleming, J.W., McConnaughey, M.M., Watanabe, A.M., 1979. Separation of vesicles of cardiac sarcolemma from vesicles of cardiac sarcoplasmic reticulum. Comparative biochemical analysis of component activities. J. Biol. Chem., 254(2):530-539.

[9] Kawano, H., Do, Y.S., Kawano, Y., Stames, V., Barr, M., Law, R.E., Hsueh, W.A., 2000. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation, 101(10):1130-1137.

[10] Kimura, Y., Kurzydlowski, K., Tada, M., MacLennan, D.H., 1996. Phospholamban regulates the Ca²⁺-ATPase through intramembrance interaction. J. Biol. Chem., 271(42):21726-21731.

[11] Levy, D., Garrison, R.J., Savage, D.D., Kannel, W.B., Castelli, W.P., 1990. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N. Engl. J. Med., 322:1561-1566.

[12] Lim, H.W., Molkentin, J.D., 1999. Calcineurin and human heart failure [letter] [see comments]. Nat. Med., 5(3):246-247.

[13] Lim, H.W., de Windt, L.J., Steinberg, L., Taigen, T., Witt, S.A., Kimball, T.R., Molkentin, J.D., 2000. Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy. Circulation, 101:2431-2437.

[14] Molkentin, J.D., Lu, J.R., Antos, C.L., Markham, B., Richardson, J., Robbins, J., Grant, S.R., Olson, E.N., 1998. A calcineurin dependent transcriptional pathway for cardiac hypertrophy. Cell, 93(2):215-228.

[15] Movsesian, M.A., Schwinger, R.H.G., 1998. Calcium sequestration by the sarcoplasmic reticulum in heart failure. Cardiovasc. Res., 37(2):352-359.

[16] Münch, G., Bölck, B., Karczewski, P., Schwinger, R.H.G., 2002. Evidence for calcineurin-mediated regulation of SERCA 2a activity in human myocardium. J. Mol. Cell. Cardiol., 34(3):321-334.

[17] Sadoshima, J., Izumo, S., 1997. The cellular and molecular response of cardiac myocytes to mechanical stress. Ann. Rev. Physiol., 59(1):551-571.

[18] Shen, H., Mirsalimi, S.M., Weiler, J.E., 1991. Effects of mild cardiac hypertrophy, induced by volume overload in turkeys, on myocardial sarcoplasmic reticulum calcium-pump and calcium-channel activities and on the creatine kinase system. Am. J. Vet. Res., 52(9):1527-1530.

[19] Shimoyama, M., Hayashi, D., Takimoto, E., Zou, Y., Oka, T., Uozumi, H., Kudoh, S., Shibasaki, F., Yazaki, Y., Nagai, R., Komuro, I., 1999. Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation, 100(24):2449-2454.

[20] Sussman, M.A., Lim, H.W., Gude, N., Taigen, T., Olson, E.N., Robbins, J., Colbert, M.C., Gualberto, A., Wieczorek, D.F., Molkentin, J.D., 1998. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science, 281(5383):1690-1693.

[21] Tada, M., Kirchberger, M.A., Katz, A.M., 1975. Phosphorylation of a 22000-dalton component of the cardiac sarcoplasmic reticulum by adenosine 3′-5′-monophosphate-dependent protein kinase. J. Biol. Chem., 250:2640-2647.

[22] Vikstrom, K.L., Leinwand, L.A., 1996. Contractile protein mutations and heart disease. Curr. Opin. Cell Biol., 8(1):97-105.

[23] Zhang, W., Kowal, R.C., Rusnak, F., 2000. Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. Circ. Res., 84(6):722-728.